Solid Biosciences (SLDB) Income from Continuing Operations (2017 - 2024)
Historic Income from Continuing Operations for Solid Biosciences (SLDB) over the last 7 years, with Q4 2024 value amounting to -$38.0 million.
- Solid Biosciences' Income from Continuing Operations fell 8463.55% to -$38.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$120.6 million, marking a year-over-year decrease of 2418.8%. This contributed to the annual value of -$120.6 million for FY2024, which is 2418.8% down from last year.
- As of Q4 2024, Solid Biosciences' Income from Continuing Operations stood at -$38.0 million, which was down 8463.55% from -$32.9 million recorded in Q3 2024.
- In the past 5 years, Solid Biosciences' Income from Continuing Operations registered a high of -$19.0 million during Q2 2020, and its lowest value of -$38.0 million during Q4 2024.
- For the 4-year period, Solid Biosciences' Income from Continuing Operations averaged around -$25.6 million, with its median value being -$24.9 million (2023).
- As far as peak fluctuations go, Solid Biosciences' Income from Continuing Operations skyrocketed by 3761.81% in 2023, and later crashed by 8463.55% in 2024.
- Solid Biosciences' Income from Continuing Operations (Quarter) stood at -$21.4 million in 2020, then tumbled by 54.62% to -$33.0 million in 2022, then skyrocketed by 37.62% to -$20.6 million in 2023, then plummeted by 84.64% to -$38.0 million in 2024.
- Its Income from Continuing Operations was -$38.0 million in Q4 2024, compared to -$32.9 million in Q3 2024 and -$25.3 million in Q2 2024.